32 completed, 3 unknown, 3 withdrawn, 2 not yet recruiting. 43 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 43 | Completed 32, Unknown 3, Withdrawn 3, Not yet recruiting 2, Recruiting 2, Terminated 1 |
| Phase 2 | 5 | Completed 3, Not yet recruiting 1, Unknown 1 |
Follow Glucose: new trials by email Literature Review of Glucose trials Research Report on Glucose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia | Phase 1 | Not yet recruiting | Columbia University | 36 | 2027-01-01 | 2026-02-06 |
| Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance. Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution - Diabetes (DM) | Phase 1 | Recruiting | David D'Alessio, M.D. | 30 | 2025-12-30 | 2026-10-01 |
| Graded Insulin Suppression Test P&F Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min - Insulin Resistance, Hyperinsulinemia | Phase 1 | Completed | Columbia University | 20 | 2024-09-16 | 2026-10-16 |
| A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants Xeruborbactam, Cefiderocol, Xeruborbactam/Cefiderocol - Bacterial Infections | Phase 1 | Completed | Qpex Biopharma, Inc. | 60 | 2024-09-04 | 2025-11-28 |
| Dexamethasone/Pancreatic Clamp P&F Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Prediabetic State | Phase 1 | Withdrawn | Columbia University | 2024-07-01 | 2024-07-10 | |
| Human Models of Selective Insulin Resistance: Alpelisib, Part I Alpelisib 300 mg, Placebo, [1-13C] sodium acetate - Insulin Resistance, Prediabetic State | Phase 1 | Recruiting | Columbia University | 32 | 2024-04-24 | 2026-08-24 |
| A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001) MK-5720, Placebo to MK-5720, MK-8189 - Schizophrenia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 17 | 2023-09-15 | 2025-03-04 |
| Pancreatic Clamp in NAFLD Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Prediabetic State | Phase 1 | Completed | Columbia University | 18 | 2023-08-29 | 2026-01-12 |
| Safety of and Tolerability to a Sodium-free Peritoneal Dialysis Solution 30% icodextrin and 10% dextrose - Chronic Kidney Diseases | Phase 1 | Unknown | Instituto Mexicano del Seguro Social | 10 | 2023-02-03 | 2023-03-28 |
| A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants BMS-986322, Rosuvastatin, Metformin - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 76 | 2022-11-11 | 2024-03-27 |
| Icodextrin Study to Test Short-Term Safety, Tolerability and Preliminary Efficacy of Sodium-Free Solution in PD Patients Icodextrin/Dextrose - Chronic Kidney Failure | Phase 1 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 10 | 2022-10-17 | 2024-01-29 |
| Pharmacodynamics and Pharmacokinetics of Different Glucose Bead Formulations in Obese Healthy Subjects Glucose 8 g coated beads (47% w/w), Glucose 12 g coated beads (47% w/w), Glucose 16 g coated beads (47% w/w) - Obese | Phase 1 | Completed | Aphaia Pharma US LLC | 20 | 2020-09-16 | 2025-09-18 |
| The Use of Sedation Drugs in the Procedure of Administering Surfactant Without Intubation (LISA/MIST) Ketamine, Glucose - Neonatal Respiratory Distress Syndrome, Gestational Age Conditions | Phase 1 | Unknown | Medical University of Warsaw | 60 | 2020-01-01 | 2022-01-19 |
| Pleurodesis Using Hypertonic Glucose to Treat Post-operative Air Leaks 50 mL of 50% Glucose, 100 mL of 50% Glucose, 150 mL of 50% Glucose - Postoperative Air Leak | Phase 1 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 12 | 2019-09-17 | 2021-05-12 |
| First-in-human Study in Healthy Subjects CORT118335, 25 mg, Prednisone Oral Tablet, Glucose - Healthy | Phase 1 | Completed | Corcept Therapeutics | 143 | 2017-09-15 | 2019-05-24 |
| Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001) MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg - Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | Phase 1 | Completed | Merck Sharp & Dohme LLC | 69 | 2017-08-16 | 2019-11-15 |
| Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002) MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg - Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | Phase 1 | Completed | Merck Sharp & Dohme LLC | 33 | 2017-04-12 | 2019-04-01 |
| Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit Riboflavin, Dextran, UVA Light Source - Keratolysis | Phase 1 / Phase 2 | Completed | Joseph B. Ciolino, MD | 76 | 2017-03-15 | 2023-05-10 |
| A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus Insulin glulisine (U300), Insulin glulisine, Insulin aspart - Type1 Diabetes Mellitus | Phase 1 | Completed | Sanofi | 44 | 2017-02-17 | 2022-04-25 |
Showing 20 of 43. Sign in to see all of them.
Diabetes Mellitus (8) · Insulin Resistance (7) · Obesity (7) · Hyperinsulinism (5) · Diabetes Mellitus, Type 1 (4) · Diabetes Mellitus, Type 2 (4) · Non-alcoholic Fatty Liver Disease (4) · Prediabetic State (4) · Overweight (3) · Cardiovascular Diseases (2) · Acidosis, Lactic (1) · Bacterial Infections (1) · Ehlers-Danlos Syndrome (1) · Ehlers-Danlos syndrome type 3 (1) · Enthesopathy (1)
Columbia University (5) · Merck Sharp & Dohme LLC (5) · Bristol-Myers Squibb (2) · Corcept Therapeutics (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · Ain Shams University (1) · Aphaia Pharma US LLC (1) · BBB-Therapeutics B.V. (1) · David D'Alessio, M.D. (1) · Eli Lilly and Company (1) · Instituto Mexicano del Seguro Social (1) · John A. Schirger (1) · Joseph B. Ciolino, MD (1) · Manhattan Pain Medicine, PLLC (1) · Medical University of Warsaw (1)
United States (21) · Canada (3) · Germany (3) · Mexico (2) · United Kingdom (2) · Argentina (1) · Denmark (1) · Egypt (1) · France (1) · Netherlands (1) · Poland (1) · Romania (1) · Sweden (1) · Switzerland (1)
Joshua R Cook, MD, PhD (4) · Alan S. Marion, MD, PhD (1) · Alison M Hill, Ph.D (1) · Carmen Vizman (1) · Christoph Beglinger, MD (1) · Christopher W McIntyre, MD/PHD (1) · David D'Alessio, MD (1) · David G. Soergel, MD (1) · David P. Rabago, MD (1) · Gaston A Topol, Dr. (1) · Geert-Jan Groeneveld, MD, PhD (1)
PMID 21252253, PMID 21795435, PMID 21969284, PMID 22515800, PMID 23690322, PMID 23813302, PMID 24122908, PMID 24635447, PMID 24733463, PMID 28961714, PMID 30125349, PMID 31092478, PMID 31803694, PMID 32557558, PMID 35390172, PMID 39790231, PMID 41118352
P30DK063608 (3), K12DK133995 (2), 2014 (1), 2016 (1), K23AT001879 (1), K23DK140614 (1), R01DK142423 (1)